Varicella zoster virus-induced neurological disease after COVID-19 vaccination: a retrospective monocentric study.
COVID-19
SARS-CoV-2
Vaccination
Vaccine
Varicella
Zoster
Journal
Journal of neurology
ISSN: 1432-1459
Titre abrégé: J Neurol
Pays: Germany
ID NLM: 0423161
Informations de publication
Date de publication:
Apr 2022
Apr 2022
Historique:
received:
15
08
2021
accepted:
13
10
2021
revised:
12
10
2021
pubmed:
2
11
2021
medline:
25
3
2022
entrez:
1
11
2021
Statut:
ppublish
Résumé
The description of every possible adverse effect or event related to vaccines is mandatory during the ongoing worldwide COVID-19 vaccination program. Although cases of cutaneous varicella zoster virus (VZV) reactivation after COVID-19 vaccination have been increasingly reported in literature and database sets, a description of VZV-induced neurological disease (VZV-ND) is still lacking. In the present study, we retrospectively evaluated patients admitted to our clinic and diagnosed with VZV-ND during the COVID-19 vaccination campaign (January-April 2021) and in the same months in the previous two years. We identified three patients with VZV-ND after COVID-19 vaccination and 19 unvaccinated VZV-ND cases as controls. In the case-control analysis, the two groups showed no difference in clinical features, results of diagnostic investigations, and outcome. Thus, VZV reactivation with neurological involvement might be a possible event triggered by COVID-19 vaccination, but the benefit following COVID-19 vaccination overcomes significantly the potential risk associated with a VZV reactivation.
Identifiants
pubmed: 34724572
doi: 10.1007/s00415-021-10849-3
pii: 10.1007/s00415-021-10849-3
pmc: PMC8558363
doi:
Substances chimiques
COVID-19 Vaccines
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
1751-1757Informations de copyright
© 2021. The Author(s).
Références
https://www.ema.europa.eu/en/human-regulatory/overview/public-health-threats/coronavirus-disease-covid-19/treatments-vaccines/vaccines-covid-19/covid-19-vaccines-authorised#authorised-covid-19-vaccines-section
https://vaers.hhs.gov/data.html
Goss AL, Samudralwar RD, Das RR, Nath A (2021) ANA investigates: neurological complications of COVID-19 vaccines. Ann Neurol 89:856–857. https://doi.org/10.1002/ana.26065
doi: 10.1002/ana.26065
pubmed: 33710649
pmcid: 8250888
https://www.gov.uk/government/publications/coronavirus-covid-19-vaccine-adverse-reactions
Català A, Muñoz-Santos C, Galván-Casas C et al (2021) Cutaneous reactions after SARS-COV-2 vaccination: a cross-sectional Spanish nationwide study of 405 cases. Br J Dermatol. https://doi.org/10.1111/bjd.20639
doi: 10.1111/bjd.20639
pubmed: 34254291
pmcid: 8444756
Gilden D, Nagel MA, Cohrs RJ (2014) Varicella-zoster. Handb Clin Neurol 123:265–283. https://doi.org/10.1016/B978-0-444-53488-0.00012-2
doi: 10.1016/B978-0-444-53488-0.00012-2
pubmed: 25015490
pmcid: 5489072
Nagel MA, Gilden D (2014) Neurological complications of varicella zoster virus reactivation. Curr Opin Neurol 27:356–360. https://doi.org/10.1097/WCO.0000000000000092
doi: 10.1097/WCO.0000000000000092
pubmed: 24792344
pmcid: 4189810
Nagel MA, Niemeyer CS, Bubak AN (2020) Central nervous system infections produced by varicella zoster virus. Curr Opin Infect Dis 33:273–278. https://doi.org/10.1097/QCO.0000000000000647
doi: 10.1097/QCO.0000000000000647
pubmed: 32332223
Walter R, Hartmann K, Fleisch F et al (1999) Reactivation of herpesvirus infections after vaccinations? Lancet 353(9155):810. https://doi.org/10.1016/S0140-6736(99)00623-6
doi: 10.1016/S0140-6736(99)00623-6
pubmed: 10459967
Psichogiou M, Samarkos M, Mikos N, Hatzakis A (2021) Reactivation of varicella zoster virus after vaccination for SARS-CoV-2. Vaccines (Basel) 9(6):572. https://doi.org/10.3390/vaccines9060572
doi: 10.3390/vaccines9060572
Diez-Domingo J, Parikh R, Bhavsar AB et al (2021) Can COVID-19 increase the risk of herpes zoster? A narrative review. Dermatol Ther (Heidelb). https://doi.org/10.1007/s13555-021-00549-1
doi: 10.1007/s13555-021-00549-1
Furer V, Zisman D, Kibari A et al (2021) Herpes zoster following BNT162b2 mRNA Covid-19 vaccination in patients with autoimmune inflammatory rheumatic diseases: a case series. Rheumatology (Oxford). https://doi.org/10.1093/rheumatology/keab345
doi: 10.1093/rheumatology/keab345
Johnson RW, Alvarez-Pasquin MJ, Bijl M et al (2015) Herpes zoster epidemiology, management, and disease and economic burden in Europe: a multidisciplinary perspective. Ther Adv Vaccines 3:109–120. https://doi.org/10.1177/2051013615599151
doi: 10.1177/2051013615599151
pubmed: 26478818
pmcid: 4591524
Tseng HF, Bruxvoort K, Ackerson B et al (2020) The epidemiology of herpes zoster in immunocompetent, unvaccinated adults ≥50 years old: incidence, complications, hospitalization, mortality, and recurrence. J Infect Dis 222:798–806. https://doi.org/10.1093/infdis/jiz652
doi: 10.1093/infdis/jiz652
pubmed: 31830250
Polack FP, Thomas SJ, Kitchin N et al (2020) Safety and efficacy of the BNT162b2 mRNA Covid-19 vaccine. N Engl J Med 383:2603–2615. https://doi.org/10.1056/NEJMoa2034577
doi: 10.1056/NEJMoa2034577
pubmed: 33301246
pmcid: 33301246
Baden LR, El Sahly HM, Essink B et al (2021) Efficacy and safety of the mRNA-1273 SARS-CoV-2 vaccine. N Engl J Med 384:403–416. https://doi.org/10.1056/NEJMoa2035389
doi: 10.1056/NEJMoa2035389
pubmed: 33378609
pmcid: 33378609
Voysey M, Clemens SAC, Madhi SA et al (2021) Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK. Lancet 397:99–111. https://doi.org/10.1016/S0140-6736(20)32661-1
doi: 10.1016/S0140-6736(20)32661-1
pubmed: 7723445
pmcid: 7723445
Brosh-Nissimov T, Sorek N, Yeshayahu M et al (2021) (2021) Oropharyngeal shedding of herpesviruses before and after BNT162b2 mRNA vaccination against COVID-19. Vaccine 39(40):5729–5731. https://doi.org/10.1016/j.vaccine.2021.08.088
doi: 10.1016/j.vaccine.2021.08.088
pubmed: 34481701
pmcid: 8445745
Barda N, Dagan N, Ben-Shlomo Y et al (2021) Safety of the BNT162b2 mRNA Covid-19 vaccine in a nationwide setting. N Engl J Med 385:1078–1090
doi: 10.1056/NEJMoa2110475
Gnann JW Jr, Whitley RJ (2002) Clinical practice. Herpes zoster. N Engl J Med 347:340–346. https://doi.org/10.1056/NEJMcp013211
doi: 10.1056/NEJMcp013211
pubmed: 12151472
Sacco S, Ricci S, Ornello R et al (2020) Reduced admissions for cerebrovascular events during COVID-19 outbreak in Italy. Stroke 51:3746–3750. https://doi.org/10.1161/STROKEAHA.120.031293
doi: 10.1161/STROKEAHA.120.031293
pubmed: 33059543
pmcid: 7678662